<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756856</url>
  </required_header>
  <id_info>
    <org_study_id>20210006520</org_study_id>
    <nct_id>NCT04756856</nct_id>
  </id_info>
  <brief_title>Muscle-targeted Nutritional Therapy for the Recovery From COVID-19</brief_title>
  <acronym>RE-COVID</acronym>
  <official_title>Impact of a Muscle-targeted Nutritional Therapy in the Recovery of Post-discharge COVID19 Patients Suffering From Sarcopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the impact of a muscle-targeted nutritional therapy consisting of nutritional&#xD;
      counseling and high-quality whey protein-based oral nutritional supplements enriched with&#xD;
      leucine and vitamin D, on the recovery of post-COVID-19 patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical performance - chair-stand</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in chair-stand test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical performance - chair-stand</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in chair-stand test at the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body muscle mass</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in total body muscle mass during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appendicular muscle mass</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in appendicular muscle mass during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status - muscle strength</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in handgrip strength during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in fatigue as assessed by the Functional Assessment of Chronic Illness Therapy Fatigue during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy intake</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in energy intake during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-perceived quality of life</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in quality of life during the study as assessed by the 5-level EuroQol five-dimensional (EQ-5D-5L) descriptive system during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in body weight during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of 25-hydroxy-vitamin D</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in 25-hydroxy-vitamin D during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Muscle-target oral nutritional supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Muscle-target oral nutritional supplementation</intervention_name>
    <description>Patients will receive daily for 12 weeks two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D. Patients will be also followed for 12 weeks after the suspension of supplementation.</description>
    <arm_group_label>Muscle-target oral nutritional supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sarcopenia (revised European Working Group on Sarcopenia in Older People criteria)&#xD;
&#xD;
          -  Recent discharge from hospital for COVID-19&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any malignant disease during the last five years&#xD;
&#xD;
          -  Known kidney failure (previous glomerular filtration rate &lt;30 ml/min);&#xD;
&#xD;
          -  Known liver failure (Child B or C)&#xD;
&#xD;
          -  Psychiatric disease&#xD;
&#xD;
          -  Endocrine disorders associated with disorders of calcium metabolism (excluding&#xD;
             osteoporosis)&#xD;
&#xD;
          -  Indications related to the study product:&#xD;
&#xD;
        More than 10 Âµg (400 IU) of daily Vitamin D intake from medical sources. More than 500 mg&#xD;
        of daily calcium intake from medical sources. Adherence to a high energy or high protein&#xD;
        diet up or use of protein containing or amino acid containing nutritional supplements up to&#xD;
        three months before starting the study.&#xD;
&#xD;
          -  Known allergy to milk, milk products or other components of the proposed interventions&#xD;
&#xD;
          -  Indication to or ongoing artificial nutrition support&#xD;
&#xD;
          -  Inclusion in other nutrition intervention trials&#xD;
&#xD;
          -  Investigator's uncertainty about the willingness or ability of the subject to comply&#xD;
             with the protocol requirements&#xD;
&#xD;
          -  Refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuele Cereda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Policlinico San Matteo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riccardo Caccialanza, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fondazione IRCCS Policlinico San Matteo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emanuele Cereda, MD</last_name>
    <phone>0382501615</phone>
    <phone_ext>0382501615</phone_ext>
    <email>e.cereda@smatteo.pv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Riccardo Caccialanza, MD</last_name>
    <phone>0382501615</phone>
    <phone_ext>0382501615</phone_ext>
    <email>e.cereda@smatteo.pv.it</email>
  </overall_contact_backup>
  <reference>
    <citation>Rondanelli M, Cereda E, Klersy C, Faliva MA, Peroni G, Nichetti M, Gasparri C, Iannello G, Spadaccini D, Infantino V, Caccialanza R, Perna S. Improving rehabilitation in sarcopenia: a randomized-controlled trial utilizing a muscle-targeted food for special medical purposes. J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1535-1547. doi: 10.1002/jcsm.12532. Epub 2020 Sep 22.</citation>
    <PMID>32961041</PMID>
  </reference>
  <reference>
    <citation>Barichella M, Cereda E, Pinelli G, Iorio L, Caroli D, Masiero I, Ferri V, Cassani E, Bolliri C, Caronni S, Maggio M, Ortelli P, Ferrazzoli D, Maras A, Riboldazzi G, Frazzitta G, Pezzoli G. Muscle-targeted nutritional support for rehabilitation in patients with parkinsonian syndrome. Neurology. 2019 Jul 30;93(5):e485-e496. doi: 10.1212/WNL.0000000000007858. Epub 2019 Jul 5.</citation>
    <PMID>31278117</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Emanuele Cereda</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

